The NHS has made its direction of travel clear on robotic surgery. The ambition is to reach 500,000 robot-assisted procedures a year by 2035, up from around 70,000 in 2023/24. NICE conditionally approved 11 robotic systems for NHS use in April 2025, NHS England has published national guidance on programme configuration, and the NHS SBS Surgical Robots, Consumables and Related Services framework offers a compliant route to procurement.
For trust clinical leaders, medical directors and finance teams, the key question is not whether robotic surgery matters. It is how to build a business case that stands up to scrutiny from boards, finance committees and capital planning groups. That means showing a clear clinical need, a credible financial model, a practical implementation plan and a compliant route to contract. This guide sets out how to do that.
Robotic surgery is no longer a fringe innovation argument. There is now a clear link to national priorities around elective recovery, productivity, shorter hospital stays and better patient outcomes.
In April 2025, NICE conditionally approved 11 robotic systems for NHS use. These include:
That created a three-year evidence generation window, giving trusts a defined period in which adoption supports both local service improvement and the wider national evidence base. Around the same time, NHS England and GIRFT published national implementation guidance, reinforcing that robotic-assisted surgery is being treated as a structured programme rather than a series of isolated local decisions.
That matters for business case writing. Trusts are not being asked to justify a speculative technology. They instead must show how their organisation can adopt it responsibly, safely and in a way that delivers measurable benefits.
The wider policy context helps too. The NHS 10-Year Health Plan and related elective recovery thinking create a stronger backdrop for arguments around minimally invasive surgery, better throughput and improved recovery.
The SBS10238 framework runs until May 2027 and covers robotic systems, consumables and related services from three awarded suppliers: CMR Surgical, Intuitive Surgical and Medtronic. It also includes training and proctoring support, which is important because most trusts are not buying a machine alone. They are buying a delivery model.
The framework’s most practically significant feature for business case purposes is its financial model flexibility. Trusts can procure through full capital purchase, lease, rental, or a pay-per-use model. The pay-per-use option is particularly important for trusts where upfront capital is a barrier. Rather than committing £500,000 to £1.5 million in capital expenditure to acquire a system, a trust can structure the investment as a variable cost tied directly to procedure volume. This changes the business case structure, making it considerably easier to approve through a capital-constrained planning process.
Understanding which financial model is right for your trust is one of the earliest and most consequential decisions in building the business case. It shapes the financial analysis, the approval route, the contract structure, and the risk profile the board will need to accept. Getting it right at the outset saves significant rework later.
If your team is weighing up route-to-market options and framework fit, this is exactly where a stronger understanding of framework use in the NHS can make the whole business case easier to shape.
One of the most common weaknesses in robotic surgery business cases is that they begin with the appeal of the technology rather than the trust’s underlying problem.
A stronger case starts with service need. That might include long lengths of stay, theatre productivity constraints, a high proportion of open procedures, workforce pressures, variation in outcomes, or limited access to minimally invasive surgery in particular specialties. The robotic platform then becomes part of the response, rather than the centre of the story from line one.
That distinction matters because boards do not approve equipment for its own sake. Instead, they approve investment that helps solve operational and clinical problems.
For most trusts, that means defining:
The more specific this section is, the more persuasive the whole case becomes.
The clinical section should be evidence-led, but it also needs to feel local. It is not enough to say that robotic surgery can reduce length of stay or improve recovery. Those are useful points, but they only become persuasive when tied to your own specialty mix, patient flow and current challenges.
A practical clinical case usually covers three things.
Be clear about which specialties are in scope first. Urology is often an obvious starting point, but some trusts may have a stronger case in gynaecology, colorectal or upper GI work. The case should explain why those specialties are being prioritised and why the trust is ready to begin there.
This is where outcome evidence matters. Reduced length of stay, lower blood loss, fewer complications and quicker recovery are all relevant. The key is to connect those benefits to the patient groups your trust actually serves.
The NICE evidence generation window gives the timing real relevance. Trusts that move during this period are contributing to a nationally coordinated evidence base. That is a stronger message than presenting adoption as a purely local ambition.
There is also an equity angle worth including where relevant. If access to minimally invasive surgery is uneven across your geography, a robotic programme can be framed as part of improving access, not just advancing technology.
The financial analysis in an NHS robotic surgery business case has to do two things simultaneously. Firstly, it must justify the investment. Secondly, it has to demonstrate a credible return. Both are achievable, but neither is straightforward.
The investment side depends heavily on the financial model chosen from SBS10238. A capital purchase of a system at, say, £1.2 million requires a capital business case through the trust’s normal approvals process, with depreciation, maintenance, and consumables costs modelled over the system’s operational life: typically eight to ten years. The consumables cost in robotic surgery is meaningful. Each robotic procedure involves single-use instruments and drapes that add a per-procedure cost that does not apply to conventional laparoscopy.
The return is built primarily from length of stay reduction and bed day savings. A robotic prostatectomy that reduces average length of stay from four days to one day frees three bed days per procedure. At a trust performing 200 prostatectomies a year, that is 600 bed days annually. This translates into meaningful bed capacity or elective throughput gains that can be quantified against the trust’s cost per bed day. Additional return comes from reduced complication rates and associated readmission costs, reduced theatre time, and in some specialties, reduced conversion to open surgery rates.
The pay-per-use model changes this analysis significantly. Where capital is genuinely unavailable, pay-per-use converts the investment from a capital item to a variable operational cost, removes depreciation from the calculation, and aligns expenditure directly with activity. The business case under this model is essentially a cost-per-procedure comparison: what is the all-in per-procedure cost under a pay-per-use RAS arrangement versus the current cost of performing the equivalent procedure conventionally? For trusts where that comparison is favourable, pay-per-use can produce a business case that is both financially credible and operationally straightforward to approve.
Training is where many robotic surgery business cases are under-developed, and where boards and finance committees ask the most probing questions. An underutilised £1.2 million robotic system that sits underutilised because the surgical team has not reached proficiency generates no return. Evaluators know this, and a business case that does not address the training pathway in detail will not survive the scrutiny it receives.
SBS10238 includes proctoring as part of its scope. Proctoring involves experienced surgeons (typically at centres of excellence) supporting a hospital’s surgical team during the early phase of programme adoption. It is not optional. Safe and effective robotic surgery requires a structured competency development pathway. Accordingly, a business case should present that pathway explicitly: how many proctored cases are planned, over what period, with what credentialing milestones, and how ongoing competency will be maintained and assessed.
Beyond individual surgeon training, the business case should address team-level readiness. Theatre nurses, anaesthetic teams, and scrub practitioners all need RAS-specific training. The operational planning for that training has programme delivery implications that finance committees will probe. The GIRFT national guidance published in May 2025 provides a recognised framework for programme configuration that business cases can and should reference. It signals to approvers that the proposed approach aligns with national standards.
There is also a workforce sustainability argument that is underused in most RAS business cases. Robotic surgery materially reduces musculoskeletal strain and fatigue for surgeons compared to open and laparoscopic techniques. In a surgical workforce under significant pressure, the ability to sustain high-volume surgical practice over a longer career is a genuine system benefit. This belongs in the workforce section of a business case, particularly for trusts making the case to their ICB or system partners as part of a network investment argument.
Once a business case has been approved internally, SBS10238 provides a straightforward and compliant procurement route to contract. Further competition is the default. Typically, this may be a structured mini-tender between the three awarded suppliers in the relevant lot. For trusts that have a clear clinical or technical requirement that only one supplier can meet, direct award under Regulation 33 is available under the right conditions.
The framework’s coverage of consumables and services under a single agreement simplifies the contracting structure considerably. A trust does not need to run separate procurement exercises for the system, the consumables, the maintenance contract, and the training package. All of that can be structured within a single SBS10238 call-off. This reduces procurement overhead, compresses the timeline from approval to implementation, and gives the finance team a single contract to manage.
Timing matters. A trust that completes its business case and moves to procurement promptly can realistically have a system operational within the NICE evidence generation window. This contributes to the national evidence base and positions you for the stronger, permanent approval landscape that follows. A trust that delays risks missing that window and entering a more congested market as adoption accelerates towards the 2035 target.
Building a robotic surgery business case is not just a drafting exercise. It is a strategic one. The document needs to align clinical need, financial credibility, workforce planning and procurement into one argument that busy decision-makers can follow quickly.
At Bidding, we support NHS and healthcare teams with healthcare and NHS bid writing services that bring structure and clarity to complex submissions. Where the challenge is shaping the argument before writing starts, our NHS and ICB bid strategy support helps teams sharpen the case they want to make and the evidence needed to support it. And where trusts need help navigating procurement routes, our healthcare framework and DPS support can help connect the business case to a practical buying route.
Bidding Ltd © 2026
